Shenzhen Chipscreen Biosciences Co. Ltd. has divulged histone deacetylase (HDAC) inhibitors found to be potentially useful for the treatment of cancer.
Shanghai Curegene Pharmaceutical Co. Ltd. has identified thyroid hormone receptor β (THR-β) agonists that are potentially useful for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD; NAFLD), diabetes and obesity.
Scientists from the Purdue Research Foundation have prepared and tested prostate-specific membrane antigen (PSMA)-targeting ligands covalently linked to the poly(ADP-ribose) polymerase (PARP) inhibitor niraparib through a releasable, reductively cleavable NADS linker.
Researchers from Beijing University of Chinese Medicine described the role of TRIM54 in cirrhosis progression using two independent animal models of chronic liver injury – a DEN-induced rat model and a CCl4-induced mouse model of liver cirrhosis.
Therorna Shanghai Co. Ltd. has presented data on TI-0032, an anti-CD19 CAR circular RNA therapeutic delivered by lipid nanoparticles (LNPs) for the treatment of autoimmune and hematological disorders.
Antengene Corp. Ltd. has obtained IND approval from China’s National Medical Products Administration (NMPA) for ATG-201 for the treatment of B-cell related autoimmune diseases.
Syntax Bio Inc. has established a research and development collaboration with Mayo Clinic focused on advancing stem cell-derived pancreatic cell therapies for type 1 diabetes.
Phoremost Ltd. has unveiled its lead program, PMC-001, a next-generation, small-molecule microtubule-targeting agent (MTA) for primary and secondary brain cancers. PMC-001 is a highly differentiated, orally bioavailable MTA.
Sensorion SA has selected SENS-601 (GJB2-GT) as its lead program and has filed clinical trial applications to study its use for GJB2-related hearing loss. SENS-601 is an AAV-based gene therapy program, utilizing a gene therapy platform codeveloped with Institut Pasteur.
Researchers from the University of Milan and collaborators reported the discovery and preclinical profile of a first-in-class covalent PFKFB3 inhibitor designed to achieve durable and selective suppression of tumor glycolysis while potentially improving tolerability compared with nonselective or reversible glycolysis inhibitors.
RSS
